Trial
NCT06964165
A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Tesaro, Inc.
Collaborators
—
Condition
Ovarian Neoplasms
Intervention
Niraparib
Why stopped
The study stopped after meeting pre-specified futility criteria
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-26